Objective Myeloid-derived suppressor cells (MDSCs) have been identified as immunosuppressive cells in tumorrelated inflammation. However, the pathogenesis of MDSCs for autoimmune disease has not been investigated as yet. The aim of this study was to address whether MDSCs contribute to autoimmune organ injury in lupusprone mice. Methods MDSCs were analyzed by flow cytometric staining of CD11b
Abstract
Objective Myeloid-derived suppressor cells (MDSCs) have been identified as immunosuppressive cells in tumorrelated inflammation. However, the pathogenesis of MDSCs for autoimmune disease has not been investigated as yet. The aim of this study was to address whether MDSCs contribute to autoimmune organ injury in lupusprone mice. Methods MDSCs were analyzed by flow cytometric staining of CD11b
? GR-1 ? in MRL-Fas lpr mice. CD4
? T-cell proliferation assay was performed by coculture with CD11b ? GR-1 ? splenocytes. The percentage of immunosuppressive cells was examined during disease progression. Expression of chemokine receptor on immunosuppressive cells was analyzed, and chemotaxis assay was performed.
Results CD11b
? GR-1 low cells had a suppressive effect on CD4
? T-cell proliferation, which was restored by an arginase-1 inhibitor. CD11b
? GR-1 low cells increased in percentage during disease progression in kidney and blood.
The number of migrated CD11b
? GR-1 low cells increased in the presence of monocyte chemoattractant protein-1/ CCL2.
Conclusion We assessed the involvement of CD11b
Introduction Myeloid-derived suppressor cells (MDSCs), which show heterogeneous phenotypes, including immature granulocytes, monocytes/macrophages (Mu), dendritic cells (DCs), and early myeloid progenitors, have been originally identified as immunosuppressive cells in association with tumor expansion. These cells have been reported to express CD11b and GR-1 in mouse models [1] [2] [3] [4] . In tumor microenvironment, MDSCs inhibit T-cell activation via arginase (ARG)-1 and nitric oxidase activation, resulting in tumor growth [4] . Moreover, MDSCs play a critical role not only in neoplastic diseases but also in other conditions [5] [6] [7] [8] . However, the impacts of MDSCs on autoimmune disorder have not been elucidated.
It has been reported that MDSCs exist in peripheral blood and may have immunosuppressive effects in patients with inflammatory bowel disease [8] and melanoma [9] . These results indicated that MDSCs may regulate the immune response, not only within accumulated organs, but also systemically. The chemokine system plays critical roles in migration and activation in various types of cells.
Regarding chemotaxis of MDSCs, recent reports show C-C chemokine receptor 2 (CCR2) regulates the dynamics in tumor environment [10] [11] [12] .
Autoimmune diseases in MRL/MPJ-lpr/lpr (MRLFas lpr ) mice resemble human systemic lupus erythematosus (SLE), characterized by dysregulation of both cellular and humoral immunity [13] . In this model, CCR2 has been reported to contribute to the progression of autoimmune kidney injury, followed by the decreased number of macrophages (Mu) [14] . However, the pathogenesis of MDSCs, especially focused on CCR2 signaling, remains to be investigated. Moreover, it should be elucidated as to whether MDSCs regulate systemic inflammation as well as peripheral autoimmune organ injury in association with CCR2 signaling.
The aim of this study was to investigate the phenotype and function of CD11b
? GR-1 ? cells in MRL-Fas lpr mice and identify immunosuppressive cells. Moreover, the impact of CCR2 signaling on immunosuppressive cells was examined.
Materials and methods

Mice
MRL-Fas
lpr mice were obtained from Charles River Japan Inc., Atsugi, Japan. All procedures employed in the animal experiments complied with the standards set out in the Guideline for the Care and Use of Laboratory Animals in Takara-machi Campus of Kanazawa University.
Antibodies
The following antibodies were used for flow cytometry: fluorescein isothiocyanate (FITC) conjugated rat antimouse CD11b antibody, phycoerythrin (PE) conjugated rat anti-mouse Gr-1 antibody, allophycocyanin (APC) conjugated hamster anti-mouse CD11c antibody, APC conjugated rat anti-mouse CD45R/B220 antibody, biotin conjugated rat anti-mouse I-A k antibody (BD Biosciences, San Diego, CA, USA), APC conjugated rat anti-mouse F4/ 80 antibody (eBioscience, San Diego, CA, USA).
Immunohistochemical examination
Tissues for immunoperoxidase staining were snap-frozen in OCT (Miles Scientific, Naperville, IL, USA) and stored at -80°C. CD11b
? cells were examined using biotin conjugated anti-mouse CD11b monoclonal antibodies (BD Biosciences). These positive lesions were identified using the avidin-biotin complex technique (DAKO, Glostrup, Denmark).
Cell isolation and separation A single cell suspension was obtained from spleens, kidneys, and bone marrow, as described previously [15] . Following cell isolation, red blood cells were lysed using fluorescence-activated cell sorter (FACS) lysing solution (BD Biosciences). CD4
? T cells and CD11b ? cells were purified from spleen using magnetic-activated cell sorting (MACS) beads (Miltenyi Biotec., Auburn, CA, USA) according to the manufacture's protocol. 
Flow cytometric analysis
After single cells were collected as described above, cells were suspended in FACS buffer. Then, cell-surface markers were stained with 10% mouse serum blocking. The biotinylated antibodies were visualized with PerCP-Cy5.5 streptavidin (BD Biosciences). FACS data were acquired on FACSCalibur. The percentage of cells expressing cellsurface marker were determined by analyzing a minimum of 50,000 cells using FlowJo software (Tree Star, Palo Alto, CA, USA).
In vitro cell culture experiment Splenic CD4
? T cells and CD11b ? GR-1 ? cells were cocultured as described previously [7] . Briefly, CD4
? T cells and CD11b
? GR-1 ? cells were purified from MRLFas lpr mice at the age of 12 weeks, as described above. These cells were suspended in Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen, Carlsbad, CA, USA), including 100 lg/ml streptomycin and 100 U/ml penicillin. Purified CD11b
? GR-1 ? cells were first treated with mitomycin C (Nacalai Tesque Inc., Kyoto, Japan) at 10 lg/ml for 2 h at 37°C in 5% carbon dioxide (CO 2 ) cell culture incubator. CD4
? T cells were stimulated by Biocoat anti-mouse CD3-coated plate (BD Biosciences) at 1.5 9 10 6 cells/well. CD11b ? GR-1 ? cells were added to CD4
? T cells at 1:1 or different ratios. To determine the impact of arginase 1 for CD11b
? GR-1 ? cells, 0.5 mM N(omega)-hydroxy-nor-L-arginine (nor-NOHA) (Carbiochem, Gibbstown, NJ, USA) was added in some experiments. After 48 h, 10 lg/well WST-1 (Premix WST-1 Cell Proliferation Assay System; Takara Bio Inc., Tokyo, Japan) was added to each well for proliferation assay, and cells were harvested for 4 h. Absorbance was measured at 450 nm with a reference wavelength of 650 nm. The proliferative activity of the isolated CD11b
? GR-1 ? cells was subtracted to determine the activity of CD4
? T cells.
Chemotaxis assay Isolated CD11b
? GR-1 low splenocytes were resuspended at 5 9 10 6 cell/ml in RPMI 1640 medium with 0.5% BSA. The 60-ll cells were added into 8-lm pore-size chemotaxis chamber (Chemotaxicell 96; Kurabou, Osaka, Japan). The lower chamber of the 96-well plates (BD Pharmingen) was filled with 100 ll of medium containing 10 ng/ml murine recombinant monocyte chemoattractant protein (MCP)-1 (R&D, Minneapolis, MN, USA). The chamber was incubated for 2 h at 37°C in 5% CO 2 cell culture incubator. The number of cells that migrated through the filter into the lower chamber was counted using the cell counter of FACScalibur.
RT-PCR analysis
Total RNA was purified from isolated CD11b
? GR-1 low splenocytes using RNeasy mini kit (Qiagen, Valencia, CA, USA). Reverse transcription (RT) was performed with SuperScript II (Invitrogen). Multiple CCR expression was analyzed using a multiplex polymerase chain reaction (MPCR) kit for mouse chemokine receptor CCR set-1 (Maxim Biotec Inc., San Francisco, CA, USA) according to the manufacture's instruction manual.
Statistical analyses
Data represent mean ± SEM. Statistical significance was determined by analysis of variance (ANOVA) and Kruskal-Wallis analyses. Significance was judged at a P value of \0.05. ? GR-1 low cells (Fig. 1a) . These populations comprised 5.9 ± 1.0%, 1.6 ± 0.1%, and 4.6 ± 0.3%, respectively. May-Giemsa stain exhibited that CD11b ? GR-1 high cells had lobular-shaped nuclei, whereas CD11b
Results
MRL-Fas
?
GR-1 int and CD11b
? GR-1 low cells were monocytic in morphology (Fig. 1b) ? GR-1 low cells expressed F4/80, CD11c and B220 (Fig. 1c) ? T cells at the ratio of 1:1 in anti-mouse CD3-coated plates (Fig. 2a) . CD11b
? GR-1 high cells had no effect on CD4
? T-cell proliferation, whereas CD11b ? GR-1 int cells significantly induced proliferation of CD4
? T cells compared with CD4
? T cells cultured alone (CD4 only 0.09 ± 0.01, CD4 ? CD11b
? GR-1 high cells 0.08 ± 0.02, CD4 ? CD11b
? GR-1 int cells 0.40 ± 0.10). In contrast, CD11b
? GR-1 low cells significantly inhibited the proliferation of CD4
? T cells (0.03 ± 0.01) (Fig. 2a) . At the increased ratio of CD11b
? GR-1 low cells to CD4 ? T cells (2:1) the proliferation of CD4
? T cells was completely suppressed (CD4 only 0.38 ± 0.02, CD4 ? 2 9 CD11b ? GR-1 low cells 0.01 ± 0.00) (Fig. 2b) . However, no inhibitory effect of CD11b
? GR-1 low cells was shown at the ratio of 0.2:1(0.36 ± 0.01) (Fig. 2b) . To determine the impact of ARG-1 on inhibitory effects of CD11b
? GR-1 low cells, the cultured cells were treated with 0.5 mM nor-NOHA, an ARG-1 inhibitor. The supplementation of nor-NOHA restored T-cell proliferation (0.25 ± 0.04) (Fig. 2b) . These results imply that CD11b ? GR-1 low cells had the inhibitory effect on CD4
? T-cell proliferation via ARG-1 activation in MRL-Fas lpr mice.
Percentage of CD11b
? GR-1 low cells changed according to disease activity in MRL-Fas lpr mice MRL-Fas lpr mice show glomerular, tubular, and perivascular lesions at 22 weeks age (Fig. 3) [16] . To detect the localization of CD11b
? cells in peripheral organs, immunohistochemistry was performed on the spleens and kidneys of 22-week-old animals. In the spleens, CD11b
? cells were detected at perifollicular lesions (Fig. 3a) . In the kidneys, CD11b
? cells were observed at perivascular lesions (Fig. 3b) and within glomeruli (Fig. 3c) 
CD11b
? GR-1 low cells in spleen, bone marrow, kidney, and peripheral blood was analyzed during disease progression. In the spleen and bone marrow, the percentage of CD11b ? GR-1 low cells significantly increased in the early stage of the disease, then decreased according to disease activity (Fig. 3d, e) . In spleen, CD11b
? GR-1 low cells increased from 3.5 ± 0.1% of all splenocytes at 6 weeks of age to 4.6 ± 0.3% at 10 weeks of age, then decreased to 2.7 ± 0.5% at 22 weeks of age. In bone marrow, CD11b
? GR-1 low cells increased from 6.7 ± 1.0% at 6 weeks of age to 10.8 ± 0.9% at 14 weeks of age, then decreased to 8.1 ± 0.3% at 22 weeks of age. In contrast, the percentage of CD11b
? GR-1 low cells increased during disease progression in kidney and blood (Fig. 3f, g ). The percentage increased from 0.1 ± 0.0% of all kidney cells at 6 weeks of age to 2.0 ± 0.2% at 22 weeks of age, and from 2.2 ± 0.5% at 6 weeks of age to 15.2 ± 2.8% at 22 weeks of age in blood. In MRL ?? mice, the frequency of CD11b
? GR-1 low cells did not change in these organs.
CCR2 signaling contributed to migration of CD11b
GR-1 low cells
To examine whether CCR2 contributes to chemotaxis of CD11b ? GR-1 low cells in MRL-Fas lpr mice, the expression of CCR2-and MCP-1/CCL2-induced chemotaxis assay was examined. Multiple chemokine receptor expression analyses revealed that CD11b
? GR-1 low cells strongly expressed CCR4 and CCR5 and weakly expressed CCR2 mRNAs (Fig. 4a) . In the chemotaxis assay, MCP-1/CCL2 induced chemotaxis of CD11b
? GR-1 low cells (CD11b ? GR-1 low cells alone; 1125 ± 41/well, MCP-1/CCL2 added; 1434 ± 25/well) (Fig. 4b) .
Discussion
In various tumor models, the critical role of MDSCs has been reported. However, the impact of MDSCs on inflammatory disease, especially for autoimmune organ disease, has not previously been examined. In this study, proliferation of CD4
? T cells was markedly inhibited by coculture with CD11b
? GR-1 low cells and restored by ARG-1 inhibitor. These cells were monocytic in morphology and showed heterogeneous populations in phenotype. In spleen and bone marrow, the percentage of CD11b
? GR-1 low cells was increased in the early stage of the disease. In kidney and peripheral blood, the percentage of CD11b
? GR-1 low cells increased according to disease activity. CCL2/CCR2 signaling contributed to the migration of CD11b
? GR-1 low cells. Taken together, these results suggest that CD11b ? GR-1 low cells in tumor mice models [11, 17] . Moreover, the L-arginine metabolism is one of the mechanisms by which MDSCs suppress T-cell function [4] . In this regard, ARG-1 inhibitor restored CD4 ? monocytes, which expressed arginase 1, as immunosuppressive M2 Mu [18] [19] [20] . Moreover, tumor-infiltrating MDSCs have been reported to bear M1 and M2 Mu characteristics [11] . Therefore, distinct and defined markers between MDSCs and M2 Mu remain to be determined.
The percentage of CD11b ? GR-1 low cells increased in spleen, kidney, and blood in 10-week-old MRL-Fas lpr mice, suggesting these cells contribute to immune modulation. Zhu et al. [7] reported that the percentage of MDSCs in peripheral organs increased after disease induction in experimental autoimmune encephalomyelitis. In alopecia areata mice, injection of MDSCs has been reported to promote hair growth by inhibiting T-cell function [6] . These results, together with our results, indicated that MDSCs play an important role not only in neoplastic diseases but also in inflammatory diseases. In in vitro study, the low expression of CCR2 mRNAs was detected on CD11b
? GR-1 low cells. Moreover, MCP-1/CCL2 induced chemotaxis of CD11b
? GR-1 low cells. This notion was suggested in recent reports, which revealed that some chemokine receptors, including CCR2, CCR5, and CX 3 CR1, were expressed on MDSCs and contributed to chemotaxis [10] [11] [12] .
In conclusion, we assessed the involvement of CD11b 
